Active Ingredient(s): Reteplase, r-PA
FDA Approved: * October 30, 1996
Pharm Company: * CENTOCOR INC
Category: Blood Thinner (Anticoagulant)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Retavase Overview

Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them. Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.[citation needed] Reteplase was approved for use in 1996.[1] Reteplase is similar to recombinant human tis...

Read more Retavase Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Retavase Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Reteplase, r-PA
  • Injection: 10unit
  • Vial: 18.8mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Retavase: (4 results)

Sorted by National Drug Code
  • 10122-141 Retavase Kit by Chiesi USA, Inc.
  • 10122-143 Retavase Kit by Chiesi USA, Inc.
  • 24477-040 Retavase Kit by Ekr Therapeutics, Inc.
  • 24477-041 Retavase Kit by Ekr Therapeutics, Inc.

Other drugs which contain Reteplase, r-PA or a similar ingredient: (1 result)